Showing results (1-10 of 93) with videos related to
Sort By:
Pageof 10
Current Protocols in Nucleic Acid Chemistry|April 23, 2008
Large-scale preparation of conjugated oligonucleoside phosphorothioates by the high-efficiency liquid-phase (HELP) methodGian Maria BonoraMetabolic Syndrome and Related Disorders|August 24, 2016
Subclinical Hypothyroidism and Metabolic Syndrome: A Common Association by Chance or a Cardiovascular Risk Driver?Benedetta Maria Bonora, Gian Paolo FadiniCurrent Opinion in Pharmacology|December 3, 2020
Diabetes pharmacotherapy and circulating stem/progenitor cells. State of the art and evidence gapsMattia Albiero, Benedetta Maria Bonora, Gian Paolo FadiniCurrent Diabetes Reports|May 20, 2020
Euglycemic KetoacidosisBenedetta Maria Bonora, Angelo Avogaro, Gian Paolo FadiniDiabetologia|May 14, 2017
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting SystemGian Paolo Fadini, Benedetta Maria Bonora, Angelo AvogaroDiabetes, Obesity & Metabolism|May 19, 2017
Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literatureBenedetta Maria Bonora, Angelo Avogaro, Gian Paolo FadiniDiabetes, Metabolic Syndrome and Obesity : Targets and Therapy|February 6, 2020
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the EvidenceBenedetta Maria Bonora, Angelo Avogaro, Gian Paolo FadiniCancer Gene Therapy|May 1, 2004
Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein bindingSusanna Cogoi, Maurizio Ballico, Gian-Maria Bonora, et al.Current Opinion in Otolaryngology & Head and Neck Surgery|January 4, 2021
Therapeutic challenges in radiation-induced salivary gland cancersSara Ronchi, Edoardo Mastella, Barbara Vischioni, et al.Cardiovascular Diabetology|February 12, 2021
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting systemBenedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, et al.Pageof 10